Photo by yogidan2012 from unsplash
1065Background: The acquisition of ligand-independent ESR1 mutations during endocrine therapy in metastatic ER+ breast cancer is a common mechanism of resistance to endocrine treatment, particularl... Click to show full abstract
1065Background: The acquisition of ligand-independent ESR1 mutations during endocrine therapy in metastatic ER+ breast cancer is a common mechanism of resistance to endocrine treatment, particularl...
Keywords:
combination fulvestrant;
mechanism;
breast;
breast cancer;
fulvestrant chemotherapy
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!